NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
Low-dose ketamine tilts the cortical excitation–inhibition balance irrespective of systemic physiological response
This randomised, single-blind, placebo-controlled crossover preprint (n=25 healthy adults) found that low-dose ketamine flattened the resting-state EEG aperiodic exponent, an indirect proxy for a shift towards cortica...
Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants
This randomised, double-blind, placebo-controlled single ascending dose Phase I trial (n=40) assessed modified-release psilocybin (0.5 to 2 mg) in healthy adults with normal weight or overweight/obesity. The formulati...
An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression
In an open-label, single-arm dose-escalation pilot (n=14) of psilocybin-assisted therapy for bipolar II depression, psilocybin (10 mg, with 25 mg if needed) was generally well tolerated and produced significant, susta...
A longitudinal analysis of the clinical practice of ketamine assisted psychotherapy with adolescents and young adults
This longitudinal observational study (n=19) examined ketamine-assisted psychotherapy in adolescents and young adults aged 14–24 with varied emotional and relationship difficulties. Depression scores fell over repeate...
Presley Gerber underwent ibogaine treatment in Cancun, Mexico, six months before his death at 27 in a rehabilitation facility.
Gerber posted a video in March describing a “pre Ibogaine Flood Dose” in Cancun, where ibogaine is legal to possess and administer. He had spoken about depression and substance abuse, while the official cause of his d...
Low-dose ketamine tilts the cortical excitation–inhibition balance irrespective of systemic physiological response
This randomised, single-blind, placebo-controlled crossover preprint (n=25 healthy adults) found that low-dose ketamine flattened the resting-state EEG aperiodic exponent, an indirect proxy for a shift towards cortica...
Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants
This randomised, double-blind, placebo-controlled single ascending dose Phase I trial (n=40) assessed modified-release psilocybin (0.5 to 2 mg) in healthy adults with normal weight or overweight/obesity. The formulati...
Global Altered States: Sayulita
This week’s Sunday Insider: Sayulita’s beautiful, temporary counterculture & the Mexico I wish I’d discovered at 23.
Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets Botanical Drug Exclusivity
Optimi Health has Health Canada authorization for a Phase 2 trial of natural psilocybin in up to 200 adults with major depressive disorder. Dosing starts in 2027, and a new House bill could decide whether mushroom-der...
Definium trial suggests LSD could help treat anxiety; “One patient meets God. The other gets itchy.”; and Compass funds psilocybin-assisted therapist training
Plus: New Mexico program licenses first producer, and an opinion on why taking the trip out of psychedelic medicine is a mistake
Field Notes #5: ‘Psychedelics Week’ in Washington D.C.
Welcome to our fifth Field Note. As a reminder, Field Notes are timely, candid voice notes from our Founder and Editor, Josh Hardman, that give our Pα+ readers a pulse on recent developments in psychedelic drug develo...
5 Psychedelic Stories You Should Know This Week
Welcome to The Psychedelic Blog. An independent media platform covering drugs, altered states & the culture surrounding them.
Conjuring Giant Sphinxes at Burning Man to Help You Know Yourself
Mareesa Stertz turned a psychedelic journey into an immersive experience, minus the drugs. She calls the practice behind it "inner hygiene." [...] Read More...
MAPS Attends Historic FDA Hearing on Psychedelics
Washington, D.C., September 17, 2026 — The FDA’s September 14 hearing marked one of the most consequential regulatory moments for psychedelic-assisted therapy to date. The Multidisciplinary Association for Psychedelic...
The man who rescues tripped-out travellers
Hilik Magnus is the 77-year-old founder of Magnus Safety, a unique search-and-rescue service for people who find themselves in crises (usually drug-induced) while travelling.